×

RNS Number : 9773H

Oxford BioDynamics PLC

09 May 2025

 

 

 

 

Oxford BioDynamics
("OBD" or the "Company" and, together with its subsidiaries, the "Group")

OBD's Oxford Lab accredited by UKAS to run EpiSwitch® Clinical Tests in the UK

·    OBD's facility in Oxford has been accredited by UKAS as clinical lab under the ISO 15189 standard

·    Clinical validation of EpiSwitch CiRT has been completed in the Oxford lab, further improving the test result turnaround time

·    All orders for both CiRT and PSE in the UK and Europe will be processed within the UK lab

Oxford, UK – 9 May 2025 –Oxford BioDynamics Plc (AIM: OBD),a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform,announces that its UK facility in Oxford has been accredited by the United Kingdom Accreditation Service (UKAS) as a clinical laboratory under the ISO 15189 standard.

The Company is also pleased to confirm the successful completed validation of its EpiSwitch Checkpoint Inhibitor Response Test (CiRT) as a clinical test in this UK laboratory. CiRT is OBD's best-in-class stratification tool that empowers clinicians to identify which patients are likely to respond to a widely used class of immunotherapies:  immune checkpoint inhibitors. The CiRT blood test is already available in the UK, but up to now, testing was performed in OBD's US CLIA-certified facility. 

Thomas Guiel, Chief Operating Officer of OBD, said:

"The immediate benefit for cancer patients seeking a CiRT test in the UK will be the significant reduction in the elapsed time from receipt of an order to result, which will now be 3-5 days. UKAS accreditation of our clinical lab in the UK under ISO15189 is a significant milestone that underscores our dedication to delivering high-quality and timely diagnostic testing to support healthcare providers and patients in the UK and Europe, meeting the stringent ISO requirements for patient testing and data security."

The successful validation of CiRT in the UK is an important advance for OBD's British partners and customers, including its strategic partner, Bupa UK1.

This milestone completes OBD's strategy to implement clinical testing operations at its UK base, commissioned in April 2024.

More information on CiRT may be found at www.myCiRT.com.

– Ends –

References

1: Oxford BioDynamics Plc. (Oct 2023). Bupa UK to cover EpiSwitch® CiRT for customers.https://otp.tools.investis.com/clients/uk/oxford_biodynamics_plc/rns/regulatory-story.aspx?cid=2040&newsid=1726458

 

 

 

For more information:

Oxford BioDynamics PLC Iain Ross Executive Chairman Paul Stockdale, CFO	+44 (0)1865 518910
Shore Capital – Nominated Adviser and Broker Advisory: Stephane Auton / Lucy Bowden Broking: Fiona Conroy	+44 (0)20 7408 4090
WG Partners – Joint Broker David Wilson / Claes Spång / Satheesh Nadarajah / Erland Sternby	+44 (0)20 3705 9330
OAK Securities – Joint Broker Jerry Keen / Henry Clarke / Damion Carruel	+44 (0)20 3973 3678
Camarco – Financial PR Marc Cohen / Tilly Butcher / Fergus Young	+44 (0)20 3757 4980 OBDFinancial@camarco.co.uk

 

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD)is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the EpiSwitch® PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com,  X (@OxBioDynamics) or LinkedIn.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRASSIESAEISEEI

Close

×

RNS Number : 7820H

Silver Bullet Data Services Grp PLC

08 May 2025

 

8 May 2025

 

Silver Bullet Data Services Group plc

("Silverbullet", the "Company" or, together with its subsidiaries, the "Group")

 

Q1 2025 Update & New Business Wins

 

Silverbullet, a provider of AI driven digital transformation services and products, is pleased to provide an update for the quarter ended 31 March 2025.

 

The Group is pleased to report that its revenues in Q1 2025 were 15 per cent. higher than the prior comparable period, at £2.31m (unaudited) versus £2.1m, demonstrating a strong start to the year in what is typically one of the slowest quarters in the calendar.

 

 The Group is also pleased to announce that it has been awarded a significant new contract with a well-known global retail brand, worth a minimum of US$1.5 million over two years, to provide a full data management and integration programme. Under this engagement, Silverbullet will fulfil a strategic data transformation role to develop a digital customer management and activation programme aimed at driving customer growth, including data driven activities through 4D AI and Codec as the programme is rolled out.

 

Furthermore, the Group has also signed two new contracts with global brands in the beverage and FMCG sectors to implement new programmes using Silverbullet's 4D AI for digital advertising targeting, following its integration into the clients' preferred global Demand Side Platform of choice, The Trade Desk. These contracts give the Board further confidence in the trajectory of growth for its higher-margin 4D AI data revenues, which have grown by 59% versus Q1 2024.

 

Taken together, these new contract wins contribute to committed services revenues in FY 2025, representing approximately 74% of the full-year revenue target, demonstrating the Company's strong progress and ability to attract and retain high-profile clients.

 

Ian James, CEO of Silverbullet, said: 

"We are delighted to be awarded new prestigious contracts and a strong start to the year which highlight our continued global growth and international footprint. This continued demand for our products and services provides us with significant confidence for our full year revenue targets and our continued focus on driving high margin data driven revenues from our proprietary AI driven platforms." 

 

 

For further information please contact:

Silverbullet		via IFC
Ian James (CEO) / Chris Ellis (CFO)
Strand Hanson Limited – Financial and Nominated Adviser		0207 409 3494
James Spinney / James Bellman / Robert Collins
Zeus Capital Limited – Joint Broker		0203 829 5000
Simon Johnson / Jake Walker
CMC Markets – Joint Broker		0203 003 8632
Douglas Crippen
IFC Advisory		020 3934 6630
Graham Herring / Tim Metcalfe / Florence Staton		07793 839 024

 

 

About Silverbullet

Silverbullet's proprietary 4D AI advertising solution is designed to help advertisers target consumers in a "privacy-first world". The product is a natural extension to its existing services business which already serves a blue-chip client base such as a leading UK hospitality brand and a Global Brewing company, amongst many others.

 

Headquartered in London, the Group employs 85+ data specialists across five regions across the globe, including, the UK, Italy, Australia, USA and Latin America. The Group continues to look at other opportunities for expansion worldwide.

 

The Company has an established and growing solutions business with significant accumulated industry experience and a proven track record of delivering strategic digital transformation and activation services to its clients. The majority of the Board have held senior positions at global software companies and have significant industry experience across data engineering, SAAS product development and marketing.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

TSTPKOBBCBKDOPK

Close

×

RNS Number : 2969G

Eco Buildings Group PLC

28 April 2025

 

28 April 2025

 

Eco Buildings Group PLC

("Eco Buildings" or the "Company")

 

Eco Buildings Group Albania Achieves ISO 14001:2015 Certification for Environmental Management

 

Eco Buildings Group plc (the "Company" or the "Group"), a UK-listed modular construction company, is proud to announce that its Albanian subsidiary, Eco Buildings Group Albania, has been awarded the ISO 14001:2015 certification for its Environmental Management System (EMS). This internationally recognized standard underscores the Group's unwavering commitment to environmental stewardship and sustainable business practices.

 

Commitment to Environmental Excellence

 

ISO 14001:2015 is a globally acknowledged standard that provides a framework for organizations to effectively manage their environmental responsibilities. Achieving this certification demonstrates Eco Buildings Group Albania's dedication to minimizing environmental impact, complying with applicable laws and regulations, and continually improving its environmental performance.

 

The certification encompasses the production and sale of prefabricated, Glass Fibre Reinforced Gypsum (GFRG) load-bearing wall products, highlighting the Company's focus on sustainable building materials that contribute to eco-friendly construction solutions.

 

Strategic Advantage in Sustainable Construction

 

In an era where environmental considerations are paramount, obtaining ISO 14001:2015 certification positions Eco Buildings Group Albania at the forefront of sustainable construction in the region. This achievement not only enhances the Company's reputation but also provides a competitive edge in the market, as clients and partners increasingly prioritize environmental responsibility in their selection of suppliers and contractors.

 

CEO Statement

 

Sanjay Bowry, CEO of Eco Buildings Group plc, commented:

 

"Securing the ISO 14001:2015 certification is a significant milestone for Eco Buildings Group Albania and reflects our Group's overarching commitment to sustainability. This accomplishment reinforces our dedication to environmental management and aligns with our strategic vision of delivering innovative, eco-friendly building solutions. We believe that responsible environmental practices are integral to long-term success and value creation for our stakeholders."

 

Looking Ahead

 

Eco Buildings Group plc remains steadfast in its pursuit of excellence in environmental management across all its operations. The Company will continue to implement best practices, invest in sustainable technologies, and engage with stakeholders to promote environmental awareness and responsibility.

 

About Eco Buildings Group plc

Eco Buildings is a leading innovator in prefabricated, green housing products, leveraging proven technology based on GFRG panels. Our modular housing solutions cater to both affordable and high-end housing markets, combining cost efficiency, speed of construction, and sustainability. With a growing portfolio of international projects, Eco Buildings is dedicated to redefining construction for the future. 

Further information is available on Eco Buildings website: www.eco-buildings.net

 

For more information contact:

Eco Buildings Group plc Sanjay Bowry, Chief Executive Officer Fiona Hadfield, Finance Director	Tel: +44 (0) 207 380 0999
Spark Advisory Partners Limited (Nominated Adviser) Matt Davis / James Keeshan	Tel:  +44 (0) 203 368 3550
Tavira Securities Limited (Broker) Oliver Stansfield / Jonathan Evans	Tel:  +44 (0) 203 192 1739

 

Notes

The Company has acquired proven and innovative prefabricated technology which has been in development and commercial use since 2006. Eco Buildings' range of prefabricated, green housing products based on glass fibre reinforced gypsum walls ("GFRG") provides a construction solution for both affordable and high-end housing.

Eco Buildings has already secured two sales contracts with major construction companies, one in Albania, the other in Kosovo, which are expected to generate gross sales revenue of approximately up to €38 million in total per annum over the first three years (approximately €114 million in total) following Admission.

The market share for factory-based building technology is expected to grow significantly over the coming years as private developers and the public sector seek to address the substantial and growing deficit in housing stock and issues of construction cost, speed and quality and housing affordability.

 

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRABUGDSDBDDGUU

Close

×

RNS Number : 3799E

4GLOBAL PLC

10 April 2025

 

 

 

10 April 2025

 

4GLOBAL plc

("4GLOBAL" or "the Company")

UK Sport Contract Win

 

4GLOBAL, a provider of data and technology for sports, fitness and wellness organisations to optimise operational and investment decisions, is pleased to announce that, following a competitive tender, it has secured an initial 18-month contract worth c. £0.5m with UK Sport, the non-departmental public body responsible for investing in Olympic and Paralympic sports in the UK, primarily through National Governing Bodies ("NGBs").

 

Under the agreement, 4GLOBAL will lead a pilot project designed to demonstrate the business value of data and digital investments within the elite UK sporting system and accelerate digital transformation within the NGBs supported by UK Sport.

 

The pilot will facilitate insight-driven decision making by providing relevant NGBs with accurate, standardised data and improved governance frameworks. Through the project, UK Sport aims to establish a consistent approach to data, make systems work together more smoothly and lay the groundwork for AI-powered innovations in the future.

 

Delivered through 4GLOBAL's newly launched Insight.OS platform and powered by the company's vast, market-leading dataset – a combination that was key to securing the contract – the project reflects the Company's evolution from developing bespoke solutions to a scalable, product-based offering that can be configured to the needs of each client. In addition, the project will significantly enhance 4GLOBAL's data asset, with new, high-quality data sources from elite sport further strengthening its depth and breadth.

 

The pilot aims to pave the way for a scalable nationwide data platform encompassing all publicly funded NGBs in the UK and has the potential to develop into a multi-year commercial partnership, mirroring the one 4GLOBAL has in place with Sport England in the community sport space.

 

Coupled with the recently announced Sport England contract, 4GLOBAL now holds the two most significant data-led contracts in UK publicly funded sport. Together, these competitive wins reinforce the Company's position as the leading provider of sports data in the UK and the partner of choice for public bodies looking to analyse participation trends, enhance performance and maximise the impact of their investments.

 

This contract aligns with 4GLOBAL's strategic priority of transitioning to higher margin repeatable and recurring revenue Insight Solutions agreements.

 

Eloy Mazon, CEO of 4GLOBAL, commented:

 

"We are proud to be supporting UK Sport in delivering this transformative programme for NGBs. It marks another important milestone for 4GLOBAL and, alongside the recent renewal and expansion of our work with Sport England, provides further validation of our shift toward scalable, higher margin Insight Solutions agreements characterised by recurring and repeatable revenue.

 

Delivered through our Insight.OS platform and powered by our unmatched proprietary dataset, which itself is enriched by this kind of agreement, this contract cements our position as the UK leader in sport data and digital infrastructure. It demonstrates the value of our product-led model, where we are licensing our data asset and providing support to help clients unlock actionable insights, rather than building unique systems from the ground up.

 

We look forward to working closely with UK Sport and the NGBs to help shape a more connected, insight-driven future for elite sport in the UK. Importantly, this programme also provides a clear blueprint for future initiatives in our key international markets, where the need for powerful and easy-to-use data solutions like ours is growing rapidly." 

 

Contacts
 

4GLOBAL	via Alma
Eloy Mazon (CEO)   Stuart Wooller (Group Finance Director)
Spark Advisory Partners (Nominated Adviser)	+44 (0)20 3368 3554
Neil Baldwin
Canaccord Genuity (Broker)	+44 (0)20 7523 8000
Bobbie Hilliam
Alma Strategic Communications	+44 (0)20 3405 0205
Rebecca Sanders-Hewett	4global@almastrategic.com
David Ison   Louisa El-Ahwal   Josh Royston   Will Ellis Hancock

 

About 4GLOBAL

 

4GLOBAL empowers sports, fitness and wellness organisations to make faster, smarter decisions about their operations, customers and investments through data and actionable insights.

 

It operates the largest sport participation and facility database in the world, with more than 4 billion data points.

 

Sourcing data from health & fitness operators, community programmes and other structured activities through its DataHub while drawing on information from GPS location updates and wearable devices, 4GLOBAL's unique combination of data assets provides a holistic view of physical activity patterns. 

 

4GLOBAL is at the forefront of predictive modelling and advanced analytics, with the insights it generates empowering customers to drive efficiencies, improve customer relationships and make more informed strategic decisions.

 

Its customers span both the public and private sectors, including central and local governments, cities, sporting bodies, trade associations, health & fitness operators and sports clubs.

 

Key markets include North America, the UK and Europe. Its headquarters are in London with offices in Miami and Istanbul.

 

4GLOBAL was founded in 2002 and listed on AIM in 2021 under the ticker 4GBL.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

CNTPKCBQPBKDCQK

Close

×

RNS Number : 7874D

Smarttech247 Group PLC

07 April 2025

 

07 April 2025

Smarttech247 Group PLC

 

("Smarttech247", the "Group" or the "Company")

 

Smarttech247 awarded Multi-Year Framework Agreement with Major London Airport

 

Smarttech247 (AIM: S247), a multi-award-winning provider of AI-enhanced cybersecurity services providing automated managed detection and response for a portfolio of international clients, is pleased to announce it has been appointed to a multi-year cybersecurity framework agreement (the "Agreement") with a major international airport in London.

 

The Agreement has a total potential value of up to £7 million across all four suppliersover its five-year term, with a further one-year extension available. While the Agreement does not guarantee minimum spend, it establishes Smarttech247 as a trusted provider to one of the UK's most high-profile transport hubs, offering a significant opportunity to generate meaningful revenues over the life of the agreement. 

 

Each order under the Agreement will be subject to a separate call-off contract and governed by the framework's standard terms and conditions. The Agreement also provides a flexible mechanism for the customer to procure cybersecurity services from Smarttech247 as needed, including the Company's flagship VisionX platform.

 

Under the terms of the Agreement, Smarttech247 will be eligible to provide services and solutions under several categories, which include:

 

·  Cybersecurity Support Services –including 24/7 managed detection and response services, firewall maintenance, endpoint and XDR management, dark web monitoring and cybersecurity assessments.

·   Cybersecurity Products –advanced email protection, endpoint detection and response technologies and related licencing.

·   Security Information and Event Management (SIEM) –next-generation SIEM, internal pen testing, threat intelligence, data discovery and vendor security assessment tools.

 

Raluca Saceanu, CEO of Smarttech247, commented:

 

"We are delighted to have been selected for this prestigious framework with one of the UK's busiest international airports. Being selected as one of its preferred suppliers for critical cybersecurity requirements further validates our strong capabilities in managed detection and response, and our ability to support complex, critical infrastructure environments.

 

"This win reflects the Group's continued execution against its strategy to grow through high-value, long-term engagements with critical national infrastructure clients. It is also a significant opportunity for us to potentially deliver cybersecurity services in a highly regulated and high-security setting over the coming years."

 

– Ends –

 

*Smarttech247 is a recognised vendor in 2024 Gartner® Market Guide for Managed Detection and Response. 

 

 

For further information please contact:

 

Smarttech247 Group PLC	Tel: +353 21 206 6033
Ronan Murphy, Executive Chairman Raluca Saceanu, Chief Executive Officer Nicholas Lee, Finance Director
SPARK Advisory Partners Limited – Nominated Adviser	Tel: + 44 (0) 20 3368 3550
Mark Brady /Angus Campbell
Cavendish Capital Markets Limited – Corporate Broker	Tel: +44 (0) 7220 0500
Marc Milmo / Hamish Waller Tim Redfern / Sunila de Silva – Broking
Yellow Jersey PR Charles Goodwin / Annabelle Wills / Bessie Elliot	Tel: +44 (0) 20 3004 9512

 

About Smarttech247

 

Smarttech247 is a multi-award winning automated MDR (Managed Detection & Response) company. Its platform is trusted by international organisations and provides threat intelligence with managed detection and response to provide actionable insights, 24/7 threat detection, investigation and response.

 

The Group's services are geared towards proactive prevention, and it achieves this by utilising the latest technologies, along with an experienced incident response team.

 

Smarttech247's offices are located in Ireland, United Kingdom, Romania, Poland and the USA. The Company was admitted to trading on the London Stock Exchange on 15 December 2022.

 

For further information please visitwww.smarttech247.com

 

*Gartner disclaimers

 

Market Guide for Managed Detection and Response, 24 June 2024, Pete Shoard, Andrew Davies, Mitchell Schneider, Angel Berrios, Craig Lawson.

 

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

 

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the

U.S. and internationally and is used herein with permission. All rights reserved.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

AGRUPUPGCUPAGAC

Close

×

RNS Number : 7874D

Smarttech247 Group PLC

07 April 2025

 

07 April 2025

Smarttech247 Group PLC

 

("Smarttech247", the "Group" or the "Company")

 

Smarttech247 awarded Multi-Year Framework Agreement with Major London Airport

 

Smarttech247 (AIM: S247), a multi-award-winning provider of AI-enhanced cybersecurity services providing automated managed detection and response for a portfolio of international clients, is pleased to announce it has been appointed to a multi-year cybersecurity framework agreement (the "Agreement") with a major international airport in London.

 

The Agreement has a total potential value of up to £7 million across all four suppliersover its five-year term, with a further one-year extension available. While the Agreement does not guarantee minimum spend, it establishes Smarttech247 as a trusted provider to one of the UK's most high-profile transport hubs, offering a significant opportunity to generate meaningful revenues over the life of the agreement. 

 

Each order under the Agreement will be subject to a separate call-off contract and governed by the framework's standard terms and conditions. The Agreement also provides a flexible mechanism for the customer to procure cybersecurity services from Smarttech247 as needed, including the Company's flagship VisionX platform.

 

Under the terms of the Agreement, Smarttech247 will be eligible to provide services and solutions under several categories, which include:

 

·  Cybersecurity Support Services –including 24/7 managed detection and response services, firewall maintenance, endpoint and XDR management, dark web monitoring and cybersecurity assessments.

·   Cybersecurity Products –advanced email protection, endpoint detection and response technologies and related licencing.

·   Security Information and Event Management (SIEM) –next-generation SIEM, internal pen testing, threat intelligence, data discovery and vendor security assessment tools.

 

Raluca Saceanu, CEO of Smarttech247, commented:

 

"We are delighted to have been selected for this prestigious framework with one of the UK's busiest international airports. Being selected as one of its preferred suppliers for critical cybersecurity requirements further validates our strong capabilities in managed detection and response, and our ability to support complex, critical infrastructure environments.

 

"This win reflects the Group's continued execution against its strategy to grow through high-value, long-term engagements with critical national infrastructure clients. It is also a significant opportunity for us to potentially deliver cybersecurity services in a highly regulated and high-security setting over the coming years."

 

– Ends –

 

*Smarttech247 is a recognised vendor in 2024 Gartner® Market Guide for Managed Detection and Response. 

 

 

For further information please contact:

 

Smarttech247 Group PLC	Tel: +353 21 206 6033
Ronan Murphy, Executive Chairman Raluca Saceanu, Chief Executive Officer Nicholas Lee, Finance Director
SPARK Advisory Partners Limited – Nominated Adviser	Tel: + 44 (0) 20 3368 3550
Mark Brady /Angus Campbell
Cavendish Capital Markets Limited – Corporate Broker	Tel: +44 (0) 7220 0500
Marc Milmo / Hamish Waller Tim Redfern / Sunila de Silva – Broking
Yellow Jersey PR Charles Goodwin / Annabelle Wills / Bessie Elliot	Tel: +44 (0) 20 3004 9512

 

About Smarttech247

 

Smarttech247 is a multi-award winning automated MDR (Managed Detection & Response) company. Its platform is trusted by international organisations and provides threat intelligence with managed detection and response to provide actionable insights, 24/7 threat detection, investigation and response.

 

The Group's services are geared towards proactive prevention, and it achieves this by utilising the latest technologies, along with an experienced incident response team.

 

Smarttech247's offices are located in Ireland, United Kingdom, Romania, Poland and the USA. The Company was admitted to trading on the London Stock Exchange on 15 December 2022.

 

For further information please visitwww.smarttech247.com

 

*Gartner disclaimers

 

Market Guide for Managed Detection and Response, 24 June 2024, Pete Shoard, Andrew Davies, Mitchell Schneider, Angel Berrios, Craig Lawson.

 

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

 

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the

U.S. and internationally and is used herein with permission. All rights reserved.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

AGRUPUPGCUPAGAC

Close

×

RNS Number : 5742D

Silverwood Brands PLC

03 April 2025

 

 3 April 2025

Silverwood Brands plc

("Silverwood", the "Company" or, together with its subsidiaries, the "Group") 

 

Leading Balmonds product now available in Boots stores and on Boots.com

 

Silverwood Brands plc (AQSE: SLWD) is pleased to announce that Balmonds' flagship product,  Skin Salvation, is now available in Boots stores and online at Boots.com.

 

Made with beeswax, organic oils and herbal tinctures, Skin Salvation is an award winning, 100% natural barrier balm, designed to prevent and treat the symptoms of eczema, psoriasis, and other dry skin conditions.

 

Alongside Skin Salvation, Balmonds produces a range of skin care solutions, including, creams, oils and salves, all based around natural and organic active ingredients. The Balmonds range is available directly from Balmonds.co.uk, as well as through channels including Amazon and Holland & Barrett. A wider range of Balmonds products will also be available soon on Boots.com. 

 

Andrew Gerrie, Executive Director at Silverwood, said, "Balmonds is one of Silverwood's core brands. Its hero product, Skin Salvation, is now available in over 300 Boots stores, and on Boots.com.

 

Roughly 10% of people in the UK are estimated to have eczema at some point in their lives and at least 50% consider themselves as having sensitive skin. The addition of Boots to our distribution channels should help significantly increase the reach of Balmonds and our share of the market for sensitive skin solutions."

 

For more information, please contact:

 

 

Silverwood Brands Plc Andrew Gerrie Paul Hodgins	info@silverwoodbrands.com
Peterhouse Capital Limited(Aquis Corporate Adviser) Mark Anwyl Narisha Ragoonanthun Brefo Gyasi	+44 (0)20 7469 0930

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NEXFXLFBEZLXBBB

Close

×

RNS Number : 4257D

4GLOBAL PLC

03 April 2025

 

 

 

3 April 2025

 

4GLOBAL plc

("4GLOBAL" or "the Company")

Sport England Contract Renewal and Expansion
 

4GLOBAL, a provider of data and technology for sports, fitness and wellness organisations to optimise operational and investment decisions, is pleased to announce that, following a competitive tender, it has secured a contract renewal and expansion with Sport England worth up to £4m over four years in equal terms.

 

Sport England initially procured 4GLOBAL in 2021 to provide performance data from public leisure facilities through its platform, Moving Communities, a decision-support tool that uses 4GLOBAL's dataset to aid understanding of where and how people engage in physical activity, enabling a more evidence-based approach to public investment. The platform has since played a central role in programmes such as the National Leisure Recovery Fund and the Swimming Pool Support Fund, tracking over 9 million active people across 1,000+ leisure facilities daily. 

 

This new Insight Solutions contract marks a significant expansion of the Sport England Moving Communities programme, underpinned by the Company's recently launched Insight.OS platform. 4GLOBAL's dataset now goes far beyond data public leisure facilities, incorporating a wide range of external sources such as wearable movement data and participation in community events, enabling broader and more detailed insights into physical activity patterns across the population with an unprecedented level of accuracy.

 

The expansion will support the delivery of Sport England's £250 million place-based investment strategy, enabling local and national bodies to use data-driven insights to target resources more effectively, overcome barriers to physical activity, monitor impact in real time, adjust delivery where needed and demonstrate to stakeholders that funding is being deployed effectively to maximise returns and drive meaningful outcomes.

 

Under the new agreement, 4GLOBAL will provide data and actionable insight to the wider ecosystem of sport and physical activity in England, engaging national governing bodies, local authorities, sports bodies and community programme providers to enable large scale, coordinated and effective delivery.

 

The increased breadth and depth of 4GLOBAL's dataset, now the largest repository of its kind in the UK, and its proven ability to generate actionable insights, were pivotal in securing the contract renewal and expansion.

 

Eloy Mazon, 4GLOBALCEO, said:"This new agreement is a strong endorsement of our ability to deepen and expand client relationships, which continues to lower our customer acquisition costs and drive EBITDA margin improvement. It also reflects the shift in our commercial model, with multi-year, multi-million-pound contracts underpinning our transition to Annual Recurring and Repeatable Revenue.

 

"The migration of clients to Insight Solutions is already delivering meaningful profitability gains, and the strength of our dataset not only enables us to offer richer insights to partners like Sport England but also reinforces a defensible competitive moat around our business. Wins like this contribute to a growing base of forward-looking revenue and position us well for long-term growth." 

 

Contacts
 

4GLOBAL	via Alma
Eloy Mazon (CEO)
Stuart Wooller (Group Finance Director)
Spark Advisory Partners (Nominated Adviser)	+44 (0)20 3368 3554
Neil Baldwin
Canaccord Genuity (Broker)	+44 (0)20 7523 8000
Bobbie Hilliam
Alma Strategic Communications	+44 (0)20 3405 0205
Rebecca Sanders-Hewett	4global@almastrategic.com
David Ison
Louisa El-Ahwal
Josh Royston
Will Ellis Hancock

 

About 4GLOBAL

 

4GLOBAL empowers sports, fitness and wellness organisations to make faster, smarter decisions about their operations, customers and investments through data and actionable insights.

 

It operates the largest sport participation and facility database in the world, with more than 4 billion data points.

 

Sourcing data from health & fitness operators, community programmes and other structured activities through its DataHub while drawing on information from GPS location updates and wearable devices, 4GLOBAL's unique combination of data assets provides a holistic view of physical activity patterns. 

 

4GLOBAL is at the forefront of predictive modelling and advanced analytics, with the insights it generates empowering customers to drive efficiencies, improve customer relationships and make more informed strategic decisions.

 

Its customers span both the public and private sectors, including central and local governments, cities, sporting bodies, trade associations, health & fitness operators and sports clubs.

 

Key markets include North America, the UK and Europe. Its headquarters are in London with offices in Miami and Istanbul.

 

4GLOBAL was founded in 2002 and listed on AIM in 2021 under the ticker 4GBL.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

CNTQLLFBEZLZBBL

Close

×

RNS Number : 2449D

Genedrive PLC

02 April 2025

 

genedrive plc

("genedrive" or the "Company")

 

Genedrive awarded additional grant funding under the DEVOTE programme

 

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces the extension of the highly successful multi-partner grant award from Innovate UK and the UK Government's Innovation Accelerator programme.

 

The Development and Validation of Technology for Time Critical Genomic Testing ("DEVOTE") grant, saw the Company benefit from approximately £1.2m through a combination of direct grant income, in-kind partner contributions, and other aligned funding.  The DEVOTE programme provided the Company with acute care patient access and supporting infrastructure to assess the real-world clinical performance of time-critical clinical tests in NHS settings.  The programme's lead partner, the University of Manchester ("UoM"), has supported the evaluation, validation, and implementation of the Genedrive® CYP2C19 ID Kit.

 

During the DEVOTE programme the Company completed validation and UKCA certification of the Genedrive® CYP2C19-ID Kit, which was subsequently published in the Journal of Molecular Diagnostics in December 2024 and recommended in final guidance from the UK's National Institute for Health and Care Excellence ("NICE") as the rapid genetics platform of choice for use in the NHS for Clopidogrel genotyping after Ischaemic or Transient Ischaemic Attack.

 

The significant success of the DEVOTE programme has led to follow-on Innovate UK Innovation Accelerator funding to further progress the DEVOTE project, of which the Company will receive £0.2m directly over the next six months for continuation of implementation of user-led product enhancements which are expected to further improve user experiences in rapid genetic testing environments.  

 

Gino Miele, Chief Executive Officer of genedrive plc, said: "The DEVOTE programme has been an incredible success and follow-on funding provides a further opportunity for us to partner once again with the University of Manchester in continuing development of time-critical genetic test solutions.  The additional non-dilutive grant funding facilitates the mitigation of development costs that would otherwise have been absorbed by the Company."

 

For further details please contact:

 

genedrive plc	+44 (0)161 989 0245
Gino Miele: CEO / Russ Shaw: CFO
Peel Hunt LLP (Nominated Adviser and Broker)	+44 (0)20 7418 8900
James Steel
Walbrook PR Ltd (Media & Investor Relations)	+44 (0)20 7933 8780 orgenedrive@walbrookpr.com
Anna Dunphy	+44 (0)7876 741 001

 

About genedrive plc (http://www.genedriveplc.com)

 

genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the Genedrive® MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS.  The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.

 

About DEVOTE

 

The Development and Validation of Technology for Time Critical Genomic Testing (DEVOTE) Programme is a collaboration between academics, clinicians, and industry partners. It aims to accelerate the adoption of genomic technology into clinical practice by supporting companies through each aspect of the translational pathway.

Programme information is available at:

 

https://gmbusinessboard.com/news/innovation-accelerator-programme-extended-to-boost-growth-across-the-uk

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCIBMBTMTTMTBA

Close

×

RNS Number : 2449D

Genedrive PLC

02 April 2025

 

genedrive plc

("genedrive" or the "Company")

 

Genedrive awarded additional grant funding under the DEVOTE programme

 

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces the extension of the highly successful multi-partner grant award from Innovate UK and the UK Government's Innovation Accelerator programme.

 

The Development and Validation of Technology for Time Critical Genomic Testing ("DEVOTE") grant, saw the Company benefit from approximately £1.2m through a combination of direct grant income, in-kind partner contributions, and other aligned funding.  The DEVOTE programme provided the Company with acute care patient access and supporting infrastructure to assess the real-world clinical performance of time-critical clinical tests in NHS settings.  The programme's lead partner, the University of Manchester ("UoM"), has supported the evaluation, validation, and implementation of the Genedrive® CYP2C19 ID Kit.

 

During the DEVOTE programme the Company completed validation and UKCA certification of the Genedrive® CYP2C19-ID Kit, which was subsequently published in the Journal of Molecular Diagnostics in December 2024 and recommended in final guidance from the UK's National Institute for Health and Care Excellence ("NICE") as the rapid genetics platform of choice for use in the NHS for Clopidogrel genotyping after Ischaemic or Transient Ischaemic Attack.

 

The significant success of the DEVOTE programme has led to follow-on Innovate UK Innovation Accelerator funding to further progress the DEVOTE project, of which the Company will receive £0.2m directly over the next six months for continuation of implementation of user-led product enhancements which are expected to further improve user experiences in rapid genetic testing environments.  

 

Gino Miele, Chief Executive Officer of genedrive plc, said: "The DEVOTE programme has been an incredible success and follow-on funding provides a further opportunity for us to partner once again with the University of Manchester in continuing development of time-critical genetic test solutions.  The additional non-dilutive grant funding facilitates the mitigation of development costs that would otherwise have been absorbed by the Company."

 

For further details please contact:

 

genedrive plc	+44 (0)161 989 0245
Gino Miele: CEO / Russ Shaw: CFO
Peel Hunt LLP (Nominated Adviser and Broker)	+44 (0)20 7418 8900
James Steel
Walbrook PR Ltd (Media & Investor Relations)	+44 (0)20 7933 8780 orgenedrive@walbrookpr.com
Anna Dunphy	+44 (0)7876 741 001

 

About genedrive plc (http://www.genedriveplc.com)

 

genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the Genedrive® MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS.  The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.

 

About DEVOTE

 

The Development and Validation of Technology for Time Critical Genomic Testing (DEVOTE) Programme is a collaboration between academics, clinicians, and industry partners. It aims to accelerate the adoption of genomic technology into clinical practice by supporting companies through each aspect of the translational pathway.

Programme information is available at:

 

https://gmbusinessboard.com/news/innovation-accelerator-programme-extended-to-boost-growth-across-the-uk

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCIBMBTMTTMTBA

Close